Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 4/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22236065 | 0.83 | PDE4A (0.37) | DGAT2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20764905 | 0.82 | GAA (0.42) | DGAT2MAP3K5RETALDH1A1LMNA | |
| SCHEMBL30602770 | 0.78 | DGAT2 (0.39) | DGAT2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1513072 | 0.78 | CMKLR1 (0.41) | DGAT2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL168052 | 0.77 | DDB1 (0.51) | MAP3K5ATRRETALDH1A1LMNA | |
| SCHEMBL24268660 | 0.77 | MAP3K5 (0.39) | DGAT2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1114562 | 0.77 | DGAT2 (0.38) | DGAT2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1513052 | 0.77 | MAP3K5 (0.37) | DGAT2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14538892 | 0.77 | GAA (0.45) | DGAT2MAP3K5ATRRETALDH1A1 | |
| SCHEMBL29879089 | 0.77 | MAP3K5 (0.39) | DGAT2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342540-A2 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Oncology Limited (IN) | 2024-03-27 | — | — | EP | disclosed |
| EP-3302448-B1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| CN-113773257-A | Substituted heterocyclic derivatives as CDK inhibitors | 奥瑞基尼探索技术有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | disclosed |
| CN-108024970-B | Substituted heterocyclic derivatives as CDK inhibitors | 奥瑞基尼探索技术有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-08-20 | — | — | US | disclosed |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-20 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| EP-3302448-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | DGAT2 3485/4885PDE4A 2195/4885PDE4B 2246/4885 |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | DGAT2 3485/4885PDE4A 2195/4885PDE4B 2246/4885 |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | DGAT2 3488/4885PDE4A 2421/4885PDE4B 2475/4885 |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | DGAT2 3488/4885PDE4A 2421/4885PDE4B 2475/4885 |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | DGAT2 3485/4885PDE4A 2195/4885PDE4B 2246/4885 |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | DGAT2 3485/4885PDE4A 2195/4885PDE4B 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.